Nanoradioenhancer NBTXR3 Shows Promising 85.7% Overall Response Rate in Phase 2 Lung Cancer Trial
NBTX has more than doubled off its 52-week low of $3.33.
Summary
Nanobiotix announced promising Part 1 data from the Johnson & Johnson-sponsored randomized Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 inoperable non-small cell lung cancer (NSCLC). The data, presented at ESTRO 2026, showed an 85.7% overall response rate (ORR) and a 57.1% complete response rate (CRR) in 7 patients, alongside a 100% disease control rate (DCR). These initial efficacy responses are significantly higher than the very low complete response rates (<5%) typically observed with the current standard of care. This positive clinical update for a key product, developed by Nanobiotix and partnered with Johnson & Johnson, is a major catalyst for the company, validating its nanotherapeutic approach and expanding the potential market for NBTXR3 beyond its ongoing Phase 3 head and neck cancer study. Investors will now watch for further data from this trial and the progression of NBTXR3 through later-stage development.
At the time of this announcement, NBTX was trading at $51.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $3.33 to $57.14. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.